Roche's plans to expand the label on Xofluza have been boosted by late-stage data showing that the one-dose influenza medicine has proved to be a safe and effective treatment in otherwise healthy children.
The Swiss major revealed that the Phase III MINISTONE-2 study met its primary endpoint, demonstrating that Xofluza (baloxavir marboxil), given...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
